Article Versions Notes

Giommoni E, Giorgione R, Paderi A, Pellegrini E, Gambale E, Marini A, Antonuzzo A, Marconcini R, Roviello G, Matucci-Cerinic M, et al. Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients. Immuno. 2021; 1(3):253-263. https://doi.org/10.3390/immuno1030017

Giommoni, Elisa, Roberta Giorgione, Agnese Paderi, Elisa Pellegrini, Elisabetta Gambale, Andrea Marini, Andrea Antonuzzo, Riccardo Marconcini, Giandomenico Roviello, Marco Matucci-Cerinic, and et al. 2021. "Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients" Immuno 1, no. 3: 253-263. https://doi.org/10.3390/immuno1030017

Giommoni, E., Giorgione, R., Paderi, A., Pellegrini, E., Gambale, E., Marini, A., Antonuzzo, A., Marconcini, R., Roviello, G., Matucci-Cerinic, M., Capaccioli, D., Pillozzi, S., & Antonuzzo, L. (2021). Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients. Immuno, 1(3), 253-263. https://doi.org/10.3390/immuno1030017